TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Corey Davis
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics secured a $50 million private placement with institutional investors to advance clinical development of TH103 for neovascular AMD, with funds expected to support operations through Q3 2027.

Insights
KLRS   positive

Successfully raised $50 million in private placement, secured funding through Q3 2027, and demonstrated progress in clinical development of TH103 with promising initial Phase 1a data